

Tobias Eckle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298644/publications.pdf>

Version: 2024-02-01

88
papers

8,874
citations

87888

38
h-index

62596

80
g-index

89
all docs

89
docs citations

89
times ranked

10571
citing authors

#	ARTICLE	IF	CITATIONS
1	Intense light-elicited alveolar type 2-specific circadian PER2 protects from bacterial lung injury via BPIFB1. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L647-L661.	2.9	5
2	Targeting alveolar-specific succinate dehydrogenase A attenuates pulmonary inflammation during acute lung injury. FASEB Journal, 2021, 35, e21468.	0.5	20
3	Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injury. Chronobiology International, 2021, 38, 1262-1273.	2.0	5
4	Circadian Angiotensin-Like-4 as a Novel Therapy in Cardiovascular Disease. Trends in Molecular Medicine, 2021, 27, 627-629.	6.7	6
5	Transcription-independent Induction of ERBB1 through Hypoxia-inducible Factor 2A Provides Cardioprotection during Ischemia and Reperfusion. Anesthesiology, 2020, 132, 763-780.	2.5	26
6	Intense Light Pretreatment Improves Hemodynamics, Barrier Function and Inflammation in a Murine Model of Hemorrhagic Shock Lung. Military Medicine, 2020, 185, e1542-e1550.	0.8	3
7	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 901-913.	2.4	7
8	Intense light as anticoagulant therapy in humans. PLoS ONE, 2020, 15, e0244792.	2.5	4
9	A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction. Current Pharmaceutical Design, 2020, 26, 4330-4337.	1.9	2
10	A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction. Current Pharmaceutical Design, 2020, 26, 4330-4337.	1.9	7
11	Intense light as anticoagulant therapy in humans. , 2020, 15, e0244792.		0
12	Intense light as anticoagulant therapy in humans. , 2020, 15, e0244792.		0
13	Intense light as anticoagulant therapy in humans. , 2020, 15, e0244792.		0
14	Intense light as anticoagulant therapy in humans. , 2020, 15, e0244792.		0
15	Intense Light-Mediated Circadian Cardioprotection via Transcriptional Reprogramming of the Endothelium. Cell Reports, 2019, 28, 1471-1484.e11.	6.4	35
16	Circadian-Hypoxia Link and its Potential for Treatment of Cardiovascular Disease. Current Pharmaceutical Design, 2019, 25, 1075-1090.	1.9	20
17	Dose-dependent Effects of Esmolol-epinephrine Combination Therapy in Myocardial Ischemia and Reperfusion Injury. Current Pharmaceutical Design, 2019, 25, 2199-2206.	1.9	4
18	Hypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury. Nature Communications, 2018, 9, 816.	12.8	100

#	ARTICLE	IF	CITATIONS
19	The Period 2 Enhancer Nobiletin as Novel Therapy in Murine Models of Circadian Disruption Resembling Delirium*. Critical Care Medicine, 2018, 46, e600-e608.	0.9	33
20	Daytime variations in perioperative myocardial injury. Lancet, The, 2018, 391, 2104.	13.7	3
21	Diurnal variations in recovery times after general anaesthesia in children. British Journal of Anaesthesia, 2018, 121, 776-786.	3.4	6
22	The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury. Current Pharmaceutical Design, 2018, 24, 3376-3383.	1.9	23
23	A Comparison of Epinephrine, Esmolol, and the Combination of Both in Reperfusion Injury After Murine Myocardial Ischemia. FASEB Journal, 2018, 32, 512.4.	0.5	0
24	Circadian MicroRNAs in Cardioprotection. Current Pharmaceutical Design, 2017, 23, 3723-3730.	1.9	28
25	Pneumomediastinum and Bilateral Pneumothoraces Causing Respiratory Failure after Thyroid Surgery. Case Reports in Anesthesiology, 2017, 2017, 1-5.	0.4	1
26	Intense light-elicited upregulation of miR-21 facilitates glycolysis and cardioprotection through Per2-dependent mechanisms. PLoS ONE, 2017, 12, e0176243.	2.5	41
27	New "Guidance" for the Treatment of Hepatic Ischemia Reperfusion Injury Through Semaphorins and Plexins*. Critical Care Medicine, 2016, 44, 1623-1624.	0.9	2
28	The impact of sedation protocols on outcomes in critical illness. Annals of Translational Medicine, 2016, 4, 33.	1.7	3
29	ADORA2b Signaling in Cardioprotection. Journal of Nature and Science, 2016, 2, .	1.1	6
30	Next Generation of Cardiovascular Studies. Anesthesiology, 2015, 122, 486-488.	2.5	1
31	Health Implications of Disrupted Circadian Rhythms and the Potential for Daylight as Therapy. Anesthesiology, 2015, 122, 1170-1175.	2.5	60
32	Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in) Tj ETQq0 0,0 rgBT /Qyerlock 10	1.9	14
33	Circadian Rhythms in Anesthesia and Critical Care Medicine. Seminars in Cardiothoracic and Vascular Anesthesia, 2015, 19, 49-60.	1.0	50
34	Differential Tissue-Specific Function of Adora2b in Cardioprotection. Journal of Immunology, 2015, 195, 1732-1743.	0.8	34
35	About Dogs, Mice, and Men. Seminars in Cardiothoracic and Vascular Anesthesia, 2014, 18, 247-248.	1.0	3
36	Transesophageal Echocardiography in the Diagnosis of Acute Pericardial Tamponade During Hiatal Hernia Repair. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 112-114.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Identification of Hypoxia-Inducible Factor HIF-1A as Transcriptional Regulator of the A2B Adenosine Receptor during Acute Lung Injury. <i>Journal of Immunology</i> , 2014, 192, 1249-1256.	0.8	101
38	Anesthetic Cardioprotection: The Role of Adenosine. <i>Current Pharmaceutical Design</i> , 2014, 20, 5690-5695.	1.9	13
39	Cardiac Period 2 in myocardial ischemia: Clinical implications of a light dependent protein. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 667-671.	2.8	34
40	Metabolomic analysis of key central carbon metabolism carboxylic acids as their 3-nitrophenylhydrazones by UPLC/ESI-MS. <i>Electrophoresis</i> , 2013, 34, 2891-2900.	2.4	100
41	Attenuating myocardial ischemia by targeting A2B adenosine receptors. <i>Trends in Molecular Medicine</i> , 2013, 19, 345-354.	6.7	100
42	Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. <i>FASEB Journal</i> , 2013, 27, 3078-3089.	0.5	95
43	Analysis of Selected Sugars and Sugar Phosphates in Mouse Heart Tissue by Reductive Amination and Liquid Chromatography-Electrospray Ionization Mass Spectrometry. <i>Analytical Chemistry</i> , 2013, 85, 5965-5973.	6.5	45
44	Cardiac Per2 Functions as Novel Link between Fatty Acid Metabolism and Myocardial Inflammation during Ischemia and Reperfusion Injury of the Heart. <i>PLoS ONE</i> , 2013, 8, e71493.	2.5	64
45	HIF1A Reduces Acute Lung Injury by Optimizing Carbohydrate Metabolism in the Alveolar Epithelium. <i>PLoS Biology</i> , 2013, 11, e1001665.	5.6	138
46	Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. <i>Nature Medicine</i> , 2012, 18, 774-782.	30.7	278
47	Myocardial Ischemia Reperfusion Injury. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2012, 16, 123-132.	1.0	385
48	Adora2b Signaling on Bone Marrow Derived Cells Dampens Myocardial Ischemia-Reperfusion Injury. <i>Anesthesiology</i> , 2012, 116, 1245-1257.	2.5	47
49	Detrimental Role For Gel-Forming Protein MUC5AC During Acute Lung Injury. , 2011, , .		0
50	Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	7
51	Use of a Hanging Weight System for Coronary Artery Occlusion in Mice. <i>Journal of Visualized Experiments</i> , 2011, , .	0.3	21
52	The hypoxia-inflammatory link and potential drug targets. <i>Current Opinion in Anaesthesiology</i> , 2011, 24, 363-369.	2.0	52
53	Role Of Mucosal Hypoxia-Inducible Factor (HIF)1a During Acute Lung Injury. , 2011, , .		0
54	Ischemia and reperfusion—from mechanism to translation. <i>Nature Medicine</i> , 2011, 17, 1391-1401.	30.7	2,524

#	ARTICLE	IF	CITATIONS
55	Interplay of Hypoxia and A2B Adenosine Receptors in Tissue Protection. <i>Advances in Pharmacology</i> , 2011, 61, 145-186.	2.0	69
56	Toll-like Receptor Signaling during Myocardial Ischemia. <i>Anesthesiology</i> , 2011, 114, 490-492.	2.5	14
57	Signaling through the A2B Adenosine Receptor Dampens Endotoxin-Induced Acute Lung Injury. <i>Journal of Immunology</i> , 2010, 184, 5271-5279.	0.8	154
58	Selective Deletion of the A1 Adenosine Receptor Abolishes Heart-Rate Slowing Effects of Intravascular Adenosine In Vivo. <i>PLoS ONE</i> , 2009, 4, e6784.	2.5	89
59	Role of Extracellular Adenosine in Acute Lung Injury. <i>Physiology</i> , 2009, 24, 298-306.	3.1	111
60	PHD2 Mutation and Congenital Erythrocytosis with Paraganglioma. <i>New England Journal of Medicine</i> , 2009, 360, 1361-1362.	27.0	11
61	Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. <i>Blood</i> , 2009, 113, 224-232.	1.4	196
62	Hypoxia-Inducible Factor-1 Is Central to Cardioprotection. <i>Circulation</i> , 2008, 118, 166-175.	1.6	372
63	Usefulness of pressure-controlled ventilation at high inspiratory pressures to induce acute lung injury in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 295, L718-L724.	2.9	28
64	Impact of Ischemia and Reperfusion Times on Myocardial Infarct Size in Mice <i>In Vivo</i> . <i>Experimental Biology and Medicine</i> , 2008, 233, 84-93.	2.4	54
65	The HIF2A Gene in Familial Erythrocytosis. <i>New England Journal of Medicine</i> , 2008, 358, 1965-1967.	27.0	5
66	Direct Treatment of Mouse or Human Blood With Soluble 5 α -Nucleotidase Inhibits Platelet Aggregation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1477-1483.	2.4	59
67	A2B adenosine receptor dampens hypoxia-induced vascular leak. <i>Blood</i> , 2008, 111, 2024-2035.	1.4	265
68	A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 3301-15.	8.2	259
69	The Reno-Vascular A2B Adenosine Receptor Protects the Kidney from Ischemia. <i>PLoS Medicine</i> , 2008, 5, e137.	8.4	187
70	Identification of Ectonucleotidases CD39 and CD73 in Innate Protection during Acute Lung Injury. <i>Journal of Immunology</i> , 2007, 178, 8127-8137.	0.8	239
71	Contribution of E α -NTPDase1 (CD39) to renal protection from ischemia α -reperfusion injury. <i>FASEB Journal</i> , 2007, 21, 2863-2873.	0.5	140
72	CD39/Ectonucleoside Triphosphate Diphosphohydrolase 1 Provides Myocardial Protection During Cardiac Ischemia/Reperfusion Injury. <i>Circulation</i> , 2007, 116, 1784-1794.	1.6	192

#	ARTICLE	IF	CITATIONS
73	Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F475-F485.	2.7	28
74	Lack of effect of extracellular adenosine generation and signaling on renal erythropoietin secretion during hypoxia. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1501-F1511.	2.7	25
75	Upregulation of the Water Channel Aquaporin-4 as a Potential Cause of Postischemic Cell Swelling in a Murine Model of Myocardial Infarction. <i>Cardiology</i> , 2007, 107, 402-410.	1.4	39
76	Protective Role of Ecto-5'-Nucleotidase (CD73) in Renal Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 833-845.	6.1	139
77	Cardioprotection by Ecto-5'-Nucleotidase (CD73) and A2B Adenosine Receptors. <i>Circulation</i> , 2007, 115, 1581-1590.	1.6	412
78	Physiological roles for ecto-5'-nucleotidase (CD73). <i>Purinergic Signalling</i> , 2006, 2, 351-360.	2.2	443
79	Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2533-H2540.	3.2	123
80	Nucleotide Metabolism and Cell-Cell Interactions. , 2006, 341, 73-88.		93
81	ATP Release From Activated Neutrophils Occurs via Connexin 43 and Modulates Adenosine-Dependent Endothelial Cell Function. <i>Circulation Research</i> , 2006, 99, 1100-1108.	4.5	314
82	Intraoperative metamizol as cause for acute anaphylactic collapse. <i>European Journal of Anaesthesiology</i> , 2005, 22, 810-812.	1.7	12
83	The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. <i>Journal of Clinical Virology</i> , 2004, 30, 50-56.	3.1	16
84	Ganciclovir-Resistant Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: Pitfalls of Phenotypic Diagnosis by In Vitro Selection of an UL97 Mutant Strain. <i>Journal of Infectious Diseases</i> , 2003, 187, 139-143.	4.0	73
85	High Impact of an Expanded Restriction Fragment Length Polymorphism Assay on Detection of Ganciclovir-Resistant UL97 Mutants of Human Cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 442-443.	3.2	12
86	Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. <i>Bone Marrow Transplantation</i> , 2002, 30, 433-439.	2.4	40
87	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. <i>Blood</i> , 2000, 96, 3286-3289.	1.4	94
88	Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. <i>Blood</i> , 2000, 96, 3286-3289.	1.4	2